Ureteral Stent Decompression is Associated with Decreased Length of Stay Compared to **Percutaneous Nephrostomy Tube in Patients with Obstructing Infected Ureteral Stones**

Albert S Ha, MD¹; Gregory W Hruby, PhD²; David S Han, MD, MS¹; Rainjade Chung, MD¹; Jeffrey Johnson, MD³; Isaac H Michaels, MPH²; Aaron Brant, MD³; Christina Sze, MD, MS³; Ananias M Burgos, MD³; Spyridon Basourakos, MD³; Patrick Lewicki, MD³; Timothy McClure, MD, MPH³; and Ojas Shah, MD¹

COLUMBIA UNIVERSITY DATA SCIENCE INSTITUTE

Introduction and Purpose

- Obstructing ureteral stone with urinary tract infection is a urologic emergency requiring prompt decompression to prevent renal impairment, severe morbidity, and mortality.
- The American Urologic Association recommends drainage of the obstructed kidney with either a ureteral stent or percutaneous nephrostomy tube (PCN) to prevent adverse outcomes.¹
- The advantages between ureteral stent vs. PCN are less established and at the discretion of the urologist.
- We compared patient and hospital-related outcomes in the management of obstructing infected ureteral stones via ureteral stent vs. PCN.




Figure 2. Consort Flow Diagram for Case Selection **Cohort Selection:**

- Non-administrative clinical data were used to construct a regular expression algorithm extracting urologic features from CT reports: Genitourinary and Impression sections, ureteral stones, hydronephrosis, stranding, and presence of staghorn stone.
- Using a 5% random sample of labeled obstructive and non-obstructive ureteral stones, the positive (PPV) and negative predictive values (NPV) were calculated to evaluate the expression algorithm.
- Overall, the obstructive nephrolithiasis phenotype had a PPV of 91.8% and NPV of 84.9%
- To identify cases of obstructing ureteral stone with urinary tract infection, the cohort was further defined by ED visit with a positive CT, positive urine culture, and treated with either ureteral stent or PCN placement (2012-2020)

¹ Columbia University Irving Medical Center, Department of Urology, New York, NY ² New York Presbyterian Analytics Department, New York, NY ³ Weill Cornell Medical College, Department of Urology, New York, NY

Non-Hi

Black

facility_i Cornell

age_at_

time_fro

Study Design: Case-Control Study **Database**: New York-Presbyterian Enterprise Data Warehouse [1] Intensive Care Unit Utilization

[2] Positive Blood Culture

[3] Length of Stay (LOS) >4 Days

Results

	PCN	Ureteral Stent Placement	Overall	
	(N=105)	(N=415)	(N=520)	
ed_race_ethnicity_new				
Unknown	31 (29.5%)	118 (28.4%)	149 (28.7%)	
lispanic White	38 (36.2%)	122 (29.4%)	160 (30.8%)	
nic White	19 (18.1%)	101 (24.3%)	120 (23.1%)	
	9 (8.6%)	51 (12.3%)	60 (11.5%)	
	8 (7.6%)	23 (5.5%)	31 (6.0%)	
id				
	64 (61.0%)	201 (48.4%)	265 (51.0%)	
bia	41 (39.0%)	214 (51.6%)	255 (49.0%)	
	58 (55.2%)	299 (72.0%)	357 (68.7%)	
	47 (44.8%)	116 (28.0%)	163 (31.3%)	
ed				
(SD)	66.6 (16.7)	57.8 (18.9)	59.6 (18.8)	
n [Min, Max]		59.0 [16.0, 101]	61.0 [16.0, 101]	
(0D)	4.00 (4.55)	0.00 (0.00)	2.05 (2.00)	
(SD)	4.80 (4.55)		3.05 (3.90)	
n [Min, Max] criteria	3.00 [0, 17.0]	1.00 [0, 15.0]	1.00 [0, 17.0]	
	28 (26.7%)	191 (46.0%)	219 (42.1%)	
	77 (73.3%)	224 (54.0%)	301 (57.9%)	
înal				
Unspecified Hydro	2 (1.9%)	15 (3.6%)	17 (3.3%)	
	33 (31.4%)	169 (40.7%)	202 (38.8%)	
ate	52 (49.5%)	192 (46.3%)	244 (46.9%)	
e	18 (17.1%)	39 (9.4%)	57 (11.0%)	
om_ed_to_procedure_hours				
(SD)	67.1 (179)	38.7 (99.4)	44.4 (120)	
n [Min, Max]	15.3 [3.62, 1270]	14.4 [1.88, 1360]	14.6 [1.88, 1360]	
g	0 (0%)	4 (1.0%)	4 (0.8%)	
_blood_culture				
	36 (34.3%)	169 (40.7%)	205 (39.4%)	
	65 (61.9%)	157 (37.8%)	222 (42.7%)	
g	4 (3.8%)	89 (21.4%)	93 (17.9%)	
(SD)	11.6 (13.3)	6.35 (10.6)	7.40 (11.4)	
n [Min, Max]	7.00 [1.00, 89.0]		4.00 [0, 109]	
zation			1	
	65 (61.9%)	327 (78.8%)	392 (75.4%)	
	40 (38.1%)	88 (21.2%)	128 (24.6%)	

			sults			
Multivariable Log	istic Regression for Out		1			
C	ICU Utilizati	2015-000 12702	Positive Blood Cu		LOS <u>></u> 4 Day	11.
Covariates	OR [95% CI]	p-value	OR [95% CI]	p-value	OR [95% CI]	p-val
Decompression Type	Deference		Defenence		Defenence	
Nephrostomy Tube	Reference	-	Reference	-	Reference	
Ureteral Stent	0.63 [0.33, 1.21] 1.01 [1.00, 1.03]	0.160 0.097	0.51 [0.28, 0.90] 1.03 [1.01, 1.04]	0.021	0.37 [0.17, 0.77] 1.04 [1.02, 1.05]	<0.00
Age Sex	1.01 [1.00, 1.05]	0.097	1.05 [1.01, 1.04]	0.001	1.04 [1.02, 1.03]	\0.0
Female	Reference		Reference	-	Reference	_
Male	0.82 [0.42, 1.54]	0.540	0.61 [0.35, 1.05]	0.079	0.84 [0.42, 1.65]	0.61
Race	0.02 [0.42, 1.54]	0.540	0.01 [0.55, 1.05]	0.075	0.04 [0.42, 1.05]	0.01
Other/Unkown	Reference	-	Reference	-	Reference	-
Non-Hispanic White	-	-	-	-	0.57 [0.29, 1.12]	0.10
Hispanic White	-	-	_	-	0.56 [0.27, 1.14]	0.11
Black	-	-	_	-	-	-
Asian	-	-	_	-		-
Facility						
Academic Center 1	Reference	-	Reference	-	Reference	-
Academic Center 2	1.56 [0.88, 2.79]	0.130	-	-	-	-
Charlson Comorbidity Index	1.09 [1.01, 1.18]	0.040	0.99 [0.93, 1.06]	0.780	1.08 [0.99, 1.18]	0.08
Sepsis Criteria*	4.32 [2.36, 8.25]	< 0.001	2.67 [1.60, 4.54]	< 0.001	1.51 [0.81, 2.83]	0.19
Time to Procedure (hours)**	1.002 [0.999, 1.003]	0.230	1.002 [1.000, 1.004]	0.070	1.026 [1.013, 1.044]	< 0.00
Hydronephrosis						
None/Unspecified	Reference	-	Reference	-	Reference	-
Mild	2.84 [0.58, 21.08]	0.230	1.31 [0.38, 4.92]	0.670	1.16 [0.23, 6.20]	0.86
Moderate	2.96 [0.61, 21.81]	0.210	1.41 [0.41, 5.24]	0.590	1.46 [0.30, 7.82]	0.65
Severe	2.17 [0.38, 17.75]	0.410	0.36 [0.08, 1.61]	0.170	1.51 [0.24, 10.06]	0.66
Positive Blood Culture	-	- 1	-	i - 1	3.45 [1.91, 6.38]	< 0.00
ure 3. Backwards s comes of ureteral	-					sing
	. (Concl	usions		-	
leeting sepsis crit	oria nrolonac	d time	to decompre	eeion	and areator	
			•		U	
Charlson Comorbio	dity Index wer	e asso	clated with wo	orse ol	utcomes in pa	atien
vith obstructing inf	ected uretera	I stone	S.			
•						_
Jreteral stent place	ement was as	sociate	ed with reduce	ed LOS	S and decreas	sed
kelihood of positiv	e blood cultu	res: un	derlvina surai	cal sel	ection on par	t of t
rologist may be in		100, un	aonying oargi		oodon on par	
						. .
Strengths include t	ne use of aire		R database ar	nd larg	e sample size	es tro
wo large tertiary c	enters; weakr	nesses	include its ref	trospe	ctive, observa	ation
lesign and instituti	·			•	·	
esign and monut			tone manaye	ποπ μ	10100015	
	F	Refere	ences			
Assimos D, Krambeo	ck A, Miller NL,	et al. Sı	urgical Manage	ment of	Stones: Ameri	can
Urological Associa 2016;196(4):1161-		gical Sc	ciety Guideline	, PART	II. J Urol.	

